Opsis Therapeutics Determined To Restore Vision Loss From Retinal Diseases

Opsis Therapeutics Determined To Restore Vision Loss From Retinal Diseases
Millions of people around the world suffer from retinal diseases, a group of debilitating conditions with a major impact on daily life, causing irreversible vision loss. From performing basic functions to personal independence and mental health, vision loss affects a wide range of everyday tasks. Common to all retinal diseases is the damage to photoreceptor cells of the retina, which malfunction and disappear. However, there are currently no therapeutic options available that can restore the permanent loss of vision and blindness these conditions can cause.
The Wisconsin-based startup Opsis Therapeutics focus on discovering and developing new treatments to restore vision to patients suffering from retinal diseases. The last decade, it has become feasible to generate new photoreceptors from induced pluripotent stem cells and then transplant them into the diseased retina. The startup aim to build on this progress and move it towards new therapeutic strategies to improve standard of care for patients with retinal diseases.
Opsis is at the forefront of scientific research on retinal cell manufacturing and its application in the treatment of retinal diseases, and aim to bring together a cross-disciplinary team of internationally recognized advisors and development partners. Although still early, the startup is pioneering new approaches to treat retinal diseases and their associated vision loss. Tens of millions around the world live with these diseases, significantly reducing their quality of life, highlighting the huge potential of Opsis and their technology.

Opsis Therapeutics is a spinoff from Cellular Dynamics International (CDI) and was established on July 31, 2016. CDI made the initial seed investment and owns 51 percent of the venture, while their partner David Gamm, director of the UQ-Madison’s McPherson Eye Research Institute, owns 49 percent. Additional investments will be made as needed for full-scale development.
If you appreciate our work, consider making a contribution